SEC Form 3 · accession 0001209191-18-052338
SUTRO BIOPHARMA, INC. · STRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anik Shabbir
Officer — Chief Technical Ops. Officer
Period of report
Sep 26, 2018
Accepted (ET)
Sep 26, 2018 · 6:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001382101
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| No securities beneficially held | holding | — | — | — | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy Common Stock)F1 | $14.16 | holding | — | — | — | — | May 11, 2026 | Common Stock | 98,070 | — | D |
Explanation of responses
- F1The option vested as to 25% of the total shares on March 28, 2017 and then 2.0833% of the total shares vest monthly thereafter, with 100% of the total shares vested and exercisable on March 28, 2020, subject to the reporting person's provision of service to the issuer on each vesting date.